Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice

Gary Wong, Xiangguo Qiu, Hideki Ebihara, Heinz Feldmann, Gary P. Kobinger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. Ebola virus (EBOV) is a lethal pathogen that causes up to 90% mortality in humans, whereas H5N1 avian influenza has a 60% fatality rate. Both viruses are considered pandemic threats. The objective was to evaluate the protective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A/Hanoi/30408/2005 H5N1 hemagglutinin and the EBOV glycoprotein (VSVΔG-HA-ZGP) in a lethal mouse model of infection. Methods. Mice were vaccinated 28 days before or 30 minutes after a lethal challenge with mouse-adapted EBOV or selected H5N1 influenza viruses from clades 0, 1, and 2. Animals were monitored for weight loss and survival, in addition to humoral and cell-mediated responses after immunization. Results. A single VSVΔG-HA-ZGP injection was efficacious when administered 28 days before a homologous H5N1 and/or mouse-adapted EBOV challenge, as well as a heterologous H5N1 challenge. Postexposure protection was only observed in vaccinated animals challenged with homologous H5N1 and/or mouse-adapted EBOV. Analysis of the adaptive immune response postvaccination revealed robust specific T- and B-cell responses, including a potent hemagglutinin inhibition antibody response against all H5N1 strains tested. Conclusions. The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly confer protection against 2 unrelated pathogens and stimulate cross-protection against H5N1 influenza viruses.

Original languageEnglish (US)
Pages (from-to)S435-S442
JournalJournal of Infectious Diseases
Volume212
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Ebolavirus
Human Influenza
Vaccines
H5N1 Subtype Influenza A Virus
Vesicular Stomatitis
Hemagglutinins
Viruses
Orthomyxoviridae
Cross Protection
Influenza in Birds
Adaptive Immunity
Pandemics
Antibody Formation
Weight Loss
Immunization
Glycoproteins
B-Lymphocytes
Injections
Survival
Mortality

Keywords

  • Ebola virus
  • H5N1 influenza virus
  • mice
  • vaccine
  • vesicular stomatitis virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice. / Wong, Gary; Qiu, Xiangguo; Ebihara, Hideki; Feldmann, Heinz; Kobinger, Gary P.

In: Journal of Infectious Diseases, Vol. 212, 01.01.2015, p. S435-S442.

Research output: Contribution to journalArticle

@article{ffaf32fde223432fac8645a74e4db9f3,
title = "Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice",
abstract = "Background. Ebola virus (EBOV) is a lethal pathogen that causes up to 90{\%} mortality in humans, whereas H5N1 avian influenza has a 60{\%} fatality rate. Both viruses are considered pandemic threats. The objective was to evaluate the protective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A/Hanoi/30408/2005 H5N1 hemagglutinin and the EBOV glycoprotein (VSVΔG-HA-ZGP) in a lethal mouse model of infection. Methods. Mice were vaccinated 28 days before or 30 minutes after a lethal challenge with mouse-adapted EBOV or selected H5N1 influenza viruses from clades 0, 1, and 2. Animals were monitored for weight loss and survival, in addition to humoral and cell-mediated responses after immunization. Results. A single VSVΔG-HA-ZGP injection was efficacious when administered 28 days before a homologous H5N1 and/or mouse-adapted EBOV challenge, as well as a heterologous H5N1 challenge. Postexposure protection was only observed in vaccinated animals challenged with homologous H5N1 and/or mouse-adapted EBOV. Analysis of the adaptive immune response postvaccination revealed robust specific T- and B-cell responses, including a potent hemagglutinin inhibition antibody response against all H5N1 strains tested. Conclusions. The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly confer protection against 2 unrelated pathogens and stimulate cross-protection against H5N1 influenza viruses.",
keywords = "Ebola virus, H5N1 influenza virus, mice, vaccine, vesicular stomatitis virus",
author = "Gary Wong and Xiangguo Qiu and Hideki Ebihara and Heinz Feldmann and Kobinger, {Gary P.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/infdis/jiv257",
language = "English (US)",
volume = "212",
pages = "S435--S442",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice

AU - Wong, Gary

AU - Qiu, Xiangguo

AU - Ebihara, Hideki

AU - Feldmann, Heinz

AU - Kobinger, Gary P.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background. Ebola virus (EBOV) is a lethal pathogen that causes up to 90% mortality in humans, whereas H5N1 avian influenza has a 60% fatality rate. Both viruses are considered pandemic threats. The objective was to evaluate the protective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A/Hanoi/30408/2005 H5N1 hemagglutinin and the EBOV glycoprotein (VSVΔG-HA-ZGP) in a lethal mouse model of infection. Methods. Mice were vaccinated 28 days before or 30 minutes after a lethal challenge with mouse-adapted EBOV or selected H5N1 influenza viruses from clades 0, 1, and 2. Animals were monitored for weight loss and survival, in addition to humoral and cell-mediated responses after immunization. Results. A single VSVΔG-HA-ZGP injection was efficacious when administered 28 days before a homologous H5N1 and/or mouse-adapted EBOV challenge, as well as a heterologous H5N1 challenge. Postexposure protection was only observed in vaccinated animals challenged with homologous H5N1 and/or mouse-adapted EBOV. Analysis of the adaptive immune response postvaccination revealed robust specific T- and B-cell responses, including a potent hemagglutinin inhibition antibody response against all H5N1 strains tested. Conclusions. The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly confer protection against 2 unrelated pathogens and stimulate cross-protection against H5N1 influenza viruses.

AB - Background. Ebola virus (EBOV) is a lethal pathogen that causes up to 90% mortality in humans, whereas H5N1 avian influenza has a 60% fatality rate. Both viruses are considered pandemic threats. The objective was to evaluate the protective efficacy of a bivalent, recombinant vesicular stomatitis virus vaccine expressing both the A/Hanoi/30408/2005 H5N1 hemagglutinin and the EBOV glycoprotein (VSVΔG-HA-ZGP) in a lethal mouse model of infection. Methods. Mice were vaccinated 28 days before or 30 minutes after a lethal challenge with mouse-adapted EBOV or selected H5N1 influenza viruses from clades 0, 1, and 2. Animals were monitored for weight loss and survival, in addition to humoral and cell-mediated responses after immunization. Results. A single VSVΔG-HA-ZGP injection was efficacious when administered 28 days before a homologous H5N1 and/or mouse-adapted EBOV challenge, as well as a heterologous H5N1 challenge. Postexposure protection was only observed in vaccinated animals challenged with homologous H5N1 and/or mouse-adapted EBOV. Analysis of the adaptive immune response postvaccination revealed robust specific T- and B-cell responses, including a potent hemagglutinin inhibition antibody response against all H5N1 strains tested. Conclusions. The results highlight the ability of vesicular stomatitis virus-vectored vaccines to rapidly confer protection against 2 unrelated pathogens and stimulate cross-protection against H5N1 influenza viruses.

KW - Ebola virus

KW - H5N1 influenza virus

KW - mice

KW - vaccine

KW - vesicular stomatitis virus

UR - http://www.scopus.com/inward/record.url?scp=84943239021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943239021&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiv257

DO - 10.1093/infdis/jiv257

M3 - Article

VL - 212

SP - S435-S442

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

ER -